 |
Vol.62 No.2 contents | Japanese/English |
 | Full Text of PDF (291K) Article in Japanese |
- Invited Review Article -
Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer
Noriko Yanagitani11Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Since the clinical introduction of immune checkpoint inhibitors (ICI) for non-small-cell lung cancer (NSCLC), pharmacotherapy for lung cancer has progressed significantly. In recent years, first-line treatment of advanced NSCLC with no driver gene mutations or alteration has become an important treatment option for ICI monotherapy, or a combination immunotherapy including an anti-CTLA-4 antibody with platinum-based chemotherapy. Combination immunotherapy, ICIs with cytotoxic anticancer agents, has been approved in Japan due to extensive clinical trial results. When choosing appropriate combination immunotherapies, it is important to consider the efficacy and adverse events of each combination immunotherapy, as well as the patient background, PD-L1 expression, and histological type.
key words: Non-small-cell lung cancer (NSCLC), Immune checkpoint inhibitor (ICI), Combination immunotherapy, First-line, Immune related adverse event (irAE)
JJLC 62 (2): 75-80, 2022
